Literature DB >> 20504636

Noradrenaline and ATP as cotransmitters in sympathetic nerves.

G Burnstock1.   

Abstract

Evidence is presented in support of the view that adenosine 5?-triphosphate (ATP) is a cotransmitter with noradrenaline (NA) in sympathetic nerves supplying the vas deferens and a number of blood vessels. ATP is responsible for the excitatory junctional potentials (EJPs) in response to single nerve impulses and the initial twitch responses of the smooth muscle, while NA produces the longer-lasting tonic contractions. The proportions of ATP to NA vary between different sympathetic nerves; they also change during development and in some pathological conditions. Prejunctional neuromodulation of release of the two cotransmitters appears to involve independent mechanisms and is frequency dependent; this raises the question of whether ATP and NA are stored in separate vesicles or whether there are subpopulations of sympathetic nerves with a predominance of either ATP or NA. ATP and NA have synergistic postjunctional actions, whether excitatory (as in the vas deferens and most blood vessels) or inhibitory (as in rabbit coronary vessels). It is suggested that use of the term "adrenergic nerves" as a synonym for sympathetic nerves is no longer appropriate, although "adrenergic transmission" or "purinergic transmission" are still useful terms.

Entities:  

Year:  1990        PMID: 20504636     DOI: 10.1016/0197-0186(90)90158-p

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  34 in total

1.  Actin filaments play a permissive role in the inhibition of store-operated Ca2+ entry by extracellular ATP in rat brown adipocytes.

Authors:  Mariko Omatsu-Kanbe; Masaru Shibata; Takefumi Yamamoto; Takahiro Isono; Hiroshi Matsuura
Journal:  Biochem J       Date:  2004-07-15       Impact factor: 3.857

2.  Discovery of purinergic signalling, the initial resistance and current explosion of interest.

Authors:  G Burnstock
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

3.  Expression of pannexin isoforms in the systemic murine arterial network.

Authors:  Alexander W Lohman; Marie Billaud; Adam C Straub; Scott R Johnstone; Angela K Best; Monica Lee; Kevin Barr; Silvia Penuela; Dale W Laird; Brant E Isakson
Journal:  J Vasc Res       Date:  2012-06-26       Impact factor: 1.934

4.  Adrenergic and purinergic components in bisected vas deferens from spontaneously hypertensive rats.

Authors:  M Guitart; J Giraldo; E Goñalons; E Vila; A Badia
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

Review 5.  NPY and stress 30 years later: the peripheral view.

Authors:  Dalay Hirsch; Zofia Zukowska
Journal:  Cell Mol Neurobiol       Date:  2012-01-24       Impact factor: 5.046

6.  Photobiomodulation therapy reduces apoptotic factors and increases glutathione levels in a neuropathic pain model.

Authors:  Atousa Janzadeh; Farinaz Nasirinezhad; Masoume Masoumipoor; Seyed Behnameldin Jameie; Parisa Hayat
Journal:  Lasers Med Sci       Date:  2016-09-17       Impact factor: 3.161

7.  Selective enhancement by an adenosine A1 receptor agonist of agents inducing contraction of the rat vas deferens.

Authors:  V R Brownhill; S M Hourani; I Kitchen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-04       Impact factor: 3.000

Review 8.  Cardiac purinergic signalling in health and disease.

Authors:  Geoffrey Burnstock; Amir Pelleg
Journal:  Purinergic Signal       Date:  2014-12-20       Impact factor: 3.765

9.  Vascular smooth muscle cells from small human omental arteries express P2X1 and P2X4 receptor subunits.

Authors:  Claire M Nichols; Oleksandr V Povstyan; Anthony P Albert; Dmitry V Gordienko; Omar Khan; Georgios Vasilikostas; Teck K Khong; Andrew Wan; Marcus Reddy; Maksym I Harhun
Journal:  Purinergic Signal       Date:  2014-05-22       Impact factor: 3.765

10.  Purinergic and adrenergic agonists synergize in stimulating vasopressin and oxytocin release.

Authors:  J R Kapoor; C D Sladek
Journal:  J Neurosci       Date:  2000-12-01       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.